Answers are grounded in this paper and cite their sources.
HOROTRAST is a colloidal solution contain-T ing 19 to 20% of thorium dioxide stabilized by dextrin, to which is added methylparahydroxybenzoate (0.15%) as a preservative. It was first introduced in radiological practice in 1928 by Bliihbaum, Frik, and Kalkbrennefl and was used as a contrast medium in a variety of radiological procedures, particularly in Germany, Switzerland, and Eastern F r a n ~e . ~ When injected intravenously, the particles of Thorotrast are taken up by cells of the reticuloendothelial system, and, as one would expect, the organs that show the greatest amount of Thorotrast after injection are the liver, spleen, bone marrow, and lymph nodes (Table During disintegration of thorium and its daughter elements, alpha, beta, and gamma radiations are emitted, and because of these radioactive properties, thorium dioxide had long been suspected as a possible carcinogenic agent in man. In fact, the carcinogenic properties of Thorotrast had been repeatedly demonstrated in experimental animals21 before Mac-Mahon and co-workers30 reported in 1947 the first malignant tumor in man that could be attributed to the injection of Thorotrast. More cases, mostly observed in European countries, were subsequently reported (Table Ours is that of a 37-year-old man, who died with a bile duct carcinoma of the liver 14 years after an injection of Thorotrast. We would like to emphasize 3 points in this report: (1) the need for a thorough follow-up of Thorotrast cases, such as has been done with cases of radium poisoning;Z. 28 (2) the fact that the liver, and not the bone, should be considered the critical organ of deposition of thorium and its daughter elements; and (3) the fact that a relatively small amount of thorium is sufficient to produce a malignant tumor.
No takes yet. Share an insight, caveat, or question.
Baserga et al. (1960) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: